Early infection in bone marrow transplantation: Quantitative study of clinical factors that affect risk

Clinical Infectious Diseases

Volumn 28, Issue 2, 1999, Pages 256-266

  Engels, Eric A ^a,b   Ellis, Charles A ^a   Supran, Stacey E ^a   Schmid, Christopher H ^a   Barza, Michael ^a   Schenkein, David P ^a   Koc, Yener ^a   Miller, Kenneth B ^a   Wong, John B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT INFECTION; HUMAN; INFECTION RATE; INFECTION RISK; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032973189     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515103     Document Type: Article

References (50)

1. 1. Rowlings PA. Autologous blood and marrow transplant registry newsletter. Milwaukee: IBMTR/ABHTR Statistical Center, 1996:6-12.
2. 2. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273-84.
3. 3. Winston DJ, Gale RP, Meyer DV, Young LS, UCLA Bone Marrow Transplantation Group. Infectious complications of human bone marrow transplantation. Medicine (Baltimore) 1979;58:1-31.
4. 4. Kirk JL, Greenfield RA, Slease B, Epstein RB. Analysis of early infectious complications after autologous bone marrow transplantation. Cancer 1988;62:2445-50.
5. 5. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996;18: 265-71.
6. 6. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
7. 7. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
8. 8. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-61.
9. 9. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994;84:1328-32.
10. 10. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992;79:2578-82.
11. 11. Blume K, Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, Amylon M. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14:S9-10.
12. 12. Ramsay NK, Kim TH, McGlave P, et al. Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia. Blood 1983;62:622-6.
13. 13. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992;80:1666-72.
14. 14. Schenkein DP, Dixon P, Desforges JF, et al. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 1994;12: 2423-31.
15. 15. McCann JC, Kanteti R, Shilepsky B, Miller KB, Sweet M, Schenkein DP. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:37-43.
16. 16. Schenkein DP, Roitman D, Miller KB, et al. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1997;3:210-6.
17. 17. Stuart RK. Autologous bone marrow transplantation for leukemia. Semin Oncol 1993;20:5(suppl 6):40-54.
18. 18. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report of the Eastern Cooperative Oncology Group. Ann Intern Med 1994;120:143-58.
19. 19. Zubrod CD, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chronic Dis 1960;11:7-33.
20. 20. Immunocompromised Host Society Design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990;161:397-401.
21. 21. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. 2nd ed. East Norwalk, Connecticut: Appleton & Lange, 1994.
22. 22. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
23. 23. Klein JP, Moeschberger ML. Survival analysis. Techniques for censored and truncated data. New York: Springer-Verlag, 1997.
24. 24. Green MS, Symons MJ. A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chron Dis 1983;36:715-24.
25. 25. Schmid CH, D'Agostino RB, Griffith JL, Beshansky JR, Selker HP. A logistic regression model when some events precede treatment: the effect of thrombolytic therapy for acute myocardial infarction on the risk of cardiac arrest. J Clin Epidemiol 1997;50:1219-29.
26. 26. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
27. 27. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofioxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-6.
28. 28. Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob Agents Chemother 1993;37:474-82.
29. 29. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1-7.
30. 30. Yamada T, Dan K, Nomura T. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med 1993;32:710-5.
31. 31. S-PLUS guide to statistical and mathematical analysis. Seattle: MathSoft, 1995.
32. 32. Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996;18:355-9.
33. 33. Sieff CA, Williams DA. Hematopoiesis. In: Handin RI, Lux SE, Stossel TP, eds. Blood. Philadelphia: JB Lippincott, 1995:171-224.
34. 34. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13:1323-7.
35. 35. Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261-6.
36. 36. Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8.
37. 37. Vartivarian S, Bodey GP. Infections associated with malignancy. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:1035-40.
38. 38. Schimpff SC. Infections in the cancer patient - diagnosis, prevention, and treatment. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2666-750.
39. 39. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-65.
40. 40. Pickering LK, Ericsson CD, Kohl S. Effect of chemotherapeutic agents on metabolic and bactericidal activity of polymorphonuclear leukocytes. Cancer 1978;42:1741-6.
41. 41. Clark RA, Johnson L, Klebanoff SJ, Thomas ED. Defective neutrophil chemotaxis in bone marrow transplant patients. J Clin Invest 1976;58: 22-31.
42. 42. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
43. 43. Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979;67: 194-200.
44. 44. Peterson PK, McGlave P, Ramsay NKC, Rhame F, Goldman Al, Kersey J. Empirical antibacterial therapy in febrile, granulocytopenic bone marrow transplant patients. Antimicrob Agents Chemother 1984;26: 136-8.
45. 45. Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986;81:237-42.
46. 46. Engels EA, Lau J, Barza M. The efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16: 1179-87.
47. 47. Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection 1991;19:73-80.
48. 48. Carratalá J, Ferńandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.
49. 49. Oppenheim BA, Hartley JW, Lee W, Burnie J. Outbreak of coagulase-negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. Br Med J 1989;299:294-7.
50. 50. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7.